RALEIGH - Opus Genetics recently announced it would open its third preclinical trial, just a few months after the company formed with a $19 million seed
RALEIGH - Opus Genetics, launched earlier this year with $19 million in invested capital, has signed an agreement to license its third preclinical program from
Athira Pharma's CEO resigns after investigation confirms she altered research during graduate school. vTv Therapeutics named healthcare investor Deepa Prasad its new CEO and president. Opus Genetics snagged a new chief scientific officer and chief operating officer.